HSBC/CALL/MODERNA/260/0.1/15.01.25 | Real-time Boerse Frankfurt Warrants 10:35:40 23/05/2024 BST | ||
| 0.76 EUR | -3.80% |
|
| Current month | +569.49% | ||
| 1 month | +740.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 0.76 | -3.80% |
| 22/05/24 | 0.79 | +139.39% |
| 21/05/24 | 0.33 | +13.79% |
| 20/05/24 | 0.29 | +45.00% |
| 17/05/24 | 0.2 | -4.76% |
Real-time Boerse Frankfurt Warrants
Last update May 23, 2024 at 10:35 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807M |
| ISIN | DE000HG807M9 |
| Date issued | 02/02/2023 |
| Strike | 260 $ |
| Maturity | 15/01/2025 (238 Days) |
| Parity | 10 : 1 |
| Emission price | 3.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.17 € |
|---|---|
| Lowest since issue | 0.044 € |
| Spread | 0.03 € |
| Spread % | 3.80% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- Warrant
